we are proud of

Our Partnerships

discussing innovative topics in antibody discovery and development

THE ANTIBODY SERIES 2024

The Antibody Series is a unique event that brings together top minds and researchers in antibody discovery and development field. After three years of success, combining superb presentations, excellent networking opportunities and festivities, The Antibody Series 2024 will be held in Madeira Island, Portugal, from September 4 – 6, 2024.

The Antibody Series provides a forum for scientific leaders to congregate and exchange valuable knowledge, meeting with expert speakers and industry peers.

TheAntibodySeries_homepageBanner (1).png

stay update with our

Latest news

fairjourney biologics

Upcoming Events

don't take our word, take theirs

Testimonials

“FairJourney Biologics was founded by a group of scientists that have a significant track record in generating therapeutic antibodies to industry standards. They have consistently impressed us with their speed and expertise.”

Mark Throsby

CSO, Merus

“I had the opportunity to work with FairJourney Biologics since last year and I am impressed by the skills and speed the different projects are delivered. I was personally involved in a project in summer 2013 in which we pulled out together 121 leads of highly specific antibodies in just 3 days. Moreover, the whole teams respires such a enthusiasm that it is a pleasure to work with FairJourney Biologics and I can recommend them to anyone looking for desired new antibodies.”

John Wijdenes

Mabdesign and CEOand consultant, AD&T consultancy

“FairJourney Biologics has demonstrated the capacity to deliver high quality antibody engineering services. The team is very experienced in phage display for the discovery of antibodies from rodent immune repertoires for diagnostic and therapeutic applications. Humanization is performed by affinity driven selections of libraries to avoid loss in potency. Desired specificity and optimal affinities can be achieved by applying appropriate selection methods thereby delivering leads useful for the development of highly specific and sensitive diagnostic assays. The outstanding track record of its research team, has enable the company to provide us with new antibodies with excellent characteristics.”

Hans de Haard

CSO, argenx

“Capella Bioscience is happy with the partnership with FairJourney Biologics for being capital efficient. Such a big antibody discovery team gives us the peace of mind, knowing that they have enough expertize to work with us.”

Steve Holmes

COO, Capella Bioscience

“FairJourney Biologics generated a comprehensive data package for a Viridian project, whereby they expressed, purified and characterized 17 lead antibody constructs. The characterization included biophysical properties, accelerated stability, solubility assessment, self-association potential, affinity determination and epitope binning. In addition, cell-based assays were developed to assess the functional potency of the lead molecules. The production and characterization were conducted in record time and enabled prioritization of top leads to progress towards manufacturing cell line generation. The FairJourney team was very responsive to our needs, provided helpful technical advice where needed, and was a pleasure to work with.”